Aprea Therapeutics, Inc. (APRE) — 10-Q Filings

10-Q Filings (6)

• Aprea Therapeutics Faces Going Concern Doubt Amid Cash Burn — Nov 12, 2025 Risk: high
  Aprea Therapeutics, Inc. reported a net loss of $2,972,410 for the three months ended September 30, 2025, an improvement from a net loss of $3,783,769 in the sa
• Aprea's Cash Dwindles, Raising Going Concern Doubts Amid Rising R&D Costs — Aug 12, 2025 Risk: high
  Aprea Therapeutics, Inc. reported a net loss of $7,171,529 for the six months ended June 30, 2025, an increase from a net loss of $6,280,143 for the same period
• Aprea Therapeutics Q1 2025 10-Q Filed — May 14, 2025 Risk: medium
  Aprea Therapeutics, Inc. filed its 10-Q for the period ending March 31, 2025. The company reported total assets of $5,512,656 and total liabilities of $56,227.
• Aprea Therapeutics Q3 2024 Update: Assets & Liabilities Detailed — Nov 7, 2024 Risk: medium
  Aprea Therapeutics, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported total assets of $5.43 million and total liabilities of $3
• Aprea Therapeutics Q2 2024 Update: Assets and Liabilities Detailed — Aug 12, 2024 Risk: medium
  Aprea Therapeutics, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported total assets of $5.43 million and total liabilities of $3.74 m
• Aprea Therapeutics, Inc. Files 10-Q for Period Ending March 31, 2024 — May 14, 2024 Risk: medium
  Aprea Therapeutics, Inc. (APRE) filed a Quarterly Report (10-Q) with the SEC on May 14, 2024. Aprea Therapeutics, Inc. filed a 10-Q report for the period ending

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX